Tempest Therapeutics, Inc. — Director's Dealing 2018

Feb 10, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2018-02-08

Reporting Person: GILLIS JONATHAN (Senior Vice President, Finance)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-08	Stock Option (right to buy)	$0.93	A	128645	Acquired	2028-02-08	Common Stock (128645)	Direct

Footnotes

F1: The option shall vest as to 25% of the shares on February 8, 2019 and the remaining shares shall vest in equal quarterly installments over 12 quarters, ending February 8, 2022.